These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 16826349

  • 1. Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago.
    Hasegawa M, Sato Y, Kanayama A, Matsuzaki K, Muraoka H, Amano A, Saika T, Kobayashi I.
    J Infect Chemother; 2006 Jun; 12(3):152-6. PubMed ID: 16826349
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activities of tosufloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella branhamella catarrhalis isolated from otolaryngological infectious diseases.
    Suzuki K, Fujisawa T, Nakashima M, Hamasaki R.
    J Infect Chemother; 2005 Oct; 11(5):253-5. PubMed ID: 16258823
    [Abstract] [Full Text] [Related]

  • 3. [Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
    Kobayashi I, Matsuzaki K, Omika K, Hasegawa M, Sato Y.
    Jpn J Antibiot; 2007 Apr; 60(2):98-106. PubMed ID: 17612257
    [Abstract] [Full Text] [Related]

  • 4. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].
    Goto H, Takeda H, Kawai S, Watanabe S, Okazaki M, Shimada K, Nakano K, Yokouchi H, Mori T, Igari J, Oguri T, Yamamoto M, Kudo K, Kobayashi N, Tanaka T, Yoshimura K, Kawabata M, Nakamori Y, Sumitomo M, Inoue H, Nakadate T, Suwabe A, Ashino Y, Aoki N, Honma Y, Suzuki Y, Karasawa Y, Oka M, Kobashi Y, Kohno S, Hirakata Y, Kondou A, Matsuda J, Nakano M, Oikawa S.
    Jpn J Antibiot; 2008 Aug; 61(4):209-40. PubMed ID: 19024644
    [Abstract] [Full Text] [Related]

  • 5. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
    Bryan JP, Waters C, Sheffield J, Wagner KF.
    Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):361-5. PubMed ID: 2142647
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
    Koeth LM, Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Appelbaum PC.
    Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
    Richard MP, Aguado AG, Mattina R, Marre R.
    J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
    [Abstract] [Full Text] [Related]

  • 14. [Recent trends in incidence of respiratory tract pathogens and antimicrobial susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis isolated in 1994 and 1995].
    Nishioka K, Ogihara H, Ohno I, Shirato K.
    Jpn J Antibiot; 1997 Sep; 50(9):768-75. PubMed ID: 9394237
    [Abstract] [Full Text] [Related]

  • 15. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H, Ito C, Yoshida T, Watanabe K, Mori T, Ohno I, Okada S, Igari J, Arakawa M, Igarashi K, Oguri T, Okada M, Ozaki K, Terai T, Aoki N, Inoue H, Nakadate T, Kitamura N, Sekine O, Suzuki Y, Ando M, Suga M, Sato K, Nakata K, Kusano N.
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
    [Abstract] [Full Text] [Related]

  • 20. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
    Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.